Minerva Neurosciences, Inc. (NERV): Shareholders' Equity
-$140.75M
As of 2025-12-31
-$213.30M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$140.75M | n/m | 2026-03-11, Balance as of period end |
| 2024-12-31 | -$25.69M | n/m | 2026-03-11, Balance as of period end |
| 2023-12-31 | -$28.46M | n/m | 2025-02-25, Balance as of period end |
| 2022-12-31 | -$20.02M | n/m | 2024-02-22, Balance as of period end |
| 2021-12-31 | $7.98M | -84.9% | 2023-03-08, Balance as of period end |
| 2020-12-31 | $52.66M | +89.6% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $27.78M | -69.2% | 2021-03-08, Balance as of period end |
| 2018-12-31 | $90.26M | -31.4% | 2020-03-09, Balance as of period end |
| 2017-12-31 | $131.60M | +24.2% | 2019-03-12, Balance as of period end |
| 2016-12-31 | $105.98M | +91.6% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $55.32M | +7.4% | 2018-03-12, Balance as of period end |
| 2014-12-31 | $51.50M | +155.2% | 2017-03-13, Balance as of period end |
| 2013-12-31 | $20.18M | n/a | 2015-03-26, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | 2025-12-31 | -$140.75M | n/m |
| iBio, Inc. (IBIO) | 2026-06-30 | $85.71M | +476.0% |
| Citius Oncology, Inc. (CTOR) | 2025-09-30 | $44.87M | -2.8% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $76.58M | -21.4% |
| Journey Medical Corp (DERM) | 2025-12-31 | $31.85M | +58.7% |
| Relmada Therapeutics, Inc. (RLMD) | 2025-12-31 | $86.51M | +143.5% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $26.15M | +7.1% |
| Tenax Therapeutics, Inc. (TENX) | 2025-12-31 | $97.07M | +5.5% |
| Immix Biopharma, Inc. (IMMX) | 2025-12-31 | $93.80M | +607.8% |
Compare NERV, IBIO, CTOR, ABUS side by side · Screen every company in Pharmaceutical Preparations ↗